B. Hafkin

发表

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

N. Kaplan, D. Nicolau, M. Banevicius, 2013, Journal of chemotherapy.

Safe coadministration of terbinafine and terfenadine: A placebo‐controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers

T. Hunt, B. Hafkin, J. Cramer, 1996, Clinical pharmacology and therapeutics.

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

N. Kaplan, J. Karlowsky, D. Hoban, 2009, Antimicrobial Agents and Chemotherapy.

Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial

R. Willke, H. Glick, A. Pleil, 2001, Pharmacotherapy.

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

M. Cynamon, B. Hafkin, M. Destefano, 2018, Antimicrobial Agents and Chemotherapy.

MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.

B. Gertz, J. Schwartz, D. Ebel, 1997, The Journal of clinical endocrinology and metabolism.

Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections

D. Stevens, J. Bruss, B. Hafkin, 2000, Antimicrobial Agents and Chemotherapy.

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

N. Kaplan, T. Hunt, B. Hafkin, 2016, Journal of chemotherapy.

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

J. Hunt, H. Lampiris, D. Stevens, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies

S. Cammarata, J. Remington, R. Isturiz, 2003, Antimicrobial Agents and Chemotherapy.

Absence of a Pharmacokinetic Interaction Between Intravenous Theophylline and Orally Administered Levofloxacin

J. Natarajan, R. R. Williams, C. Fowler, 1997, Journal of clinical pharmacology.

Hematologic Effects of Linezolid: Summary of Clinical Experience

S. Gerson, S. Kaplan, J. Bruss, 2002, Antimicrobial Agents and Chemotherapy.

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

L J Lee, B Hafkin, I D Lee, 1997, Antimicrobial agents and chemotherapy.

Effects ofInterferon andAdenine Arabinoside Treatment of Hepatitis BVirus Infection onCellular ImmuneResponses

B. Hafkin, 1979 .

Clinical experience with a human diploid cell rabies vaccine.

L. D'Angelo, R. Keenlyside, W. G. Winkler, 1980, JAMA.

Is there a future for FabI inhibitors as antibacterial agents

A. Karchmer, B Hafkin, Aw Karchmer, 2013 .

Risk factors for Guillain‐Barré syndrome

R. Holman, R. Kaslow, L. Schonberger, 1987, Neurology.

Reintroduction of dengue fever into the continental United States. I. Dengue surveillance in Texas, 1980.

C. Reed, R. Fontaine, J. Kaplan, 1982, The American journal of tropical medicine and hygiene.

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen

J. Bulitta, B. Hafkin, E. Fang, 2021, Open Forum Infectious Diseases.

Viruses in a community water supply associated with an outbreak of gastroenteritis and infectious hepatitis

Charles P. Gerba, Thomas W. Hejkal, Bruce H. Keswick, 1982 .

Cholera on the Texas Gulf Coast.

J. Peterson, M. Kelly, D. Martin, 1982, JAMA.

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

Vladimir Romanov, Molly B. Schmid, N. Kaplan, 2012, Antimicrobial Agents and Chemotherapy.

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects

P. Eckburg, B. Hafkin, Y. Ge, 2017, Antimicrobial Agents and Chemotherapy.

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

N. Kaplan, Nachum Kaplan, Barry Hafkin, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Persistence of cholera in the United States.

J. Wells, J. Taylor, P. Blake, 1983, The American journal of tropical medicine and hygiene.

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

N. Kaplan, D. Awrey, J. Yethon, 2013, Journal of chemotherapy.

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.

N. Kaplan, T. Hunt, B. Hafkin, 2015, Future microbiology.

Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities

N. Kaplan, B. Hafkin, B. Murphy, 2015, Antimicrobial Agents and Chemotherapy.

Effects of Interferon and Adenine Arabinoside Treatment of Hepatitis B Virus Infection on Cellular Immune Responses

T. Merigan, M. Tiku, W. Robinson, 1979, Antimicrobial Agents and Chemotherapy.

CRITICAL CARE PATIENTS WITH SIGNIFICANT, RESISTANT, GRAM-POSTIVE INFECTIONS ENROLLED IN THE LINEZOLID COMPASSIONATE USE PROTOCOL

Jerome J. Schentag, M. Birmingham, B. Hafkin, 1999 .

HLA antigens in Guillain‐Barré Syndrome

R. Kaslow, L. Schonberger, J. Sullivan-Bolyai, 1984, Neurology.